title: Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies.
abstract: OBJECTIVE
  We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies.
  
  
  METHODS
  A total of 45 patients with hematologic malignancies were treated using stem cell transplantation between March 2007 and June 2012. All the patients received a modified BU/CY conditioning regimen before transplantation. The outcomes of the patients were followed up including mortality, survival, relapse, and complications.
  
  
  RESULTS
  The median of follow-up duration was 527 days. All the patients who received modified BU/CY conditioning regimen achieved hematopoietic recovery successfully. Among the patients, 24 were survived without complications, 5 had relapsed hematologic malignancies, and 16 died. The median time to leucocyte engraftment was 14 days and to platelet engraftment was 12 days. Acute graft-versus-host disease (aGVHD; grades I-IV) occurred in 15 patients (30%). The cumulative incidence of grades I aGVHD was 22.2% (10 patients), grades II was 6.7% (3 patients), and grades III-IV was 4.4% (2 patients). Among 40 appreciable patients, 8 (20%) developed chronic GVHD. The incidence rate of hemorrhagic cystitis and veno-occlusive disease were 15.5% and 2.2%, respectively.
  
  
  CONCLUSIONS
  The modified BU/CY conditioning regimen for allo-HSCT is effective and safe for the treatment of hematologic malignancies.
authors.affiliation: Department of Hematology and Oncology, Children's Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: X F
authors.initials: XF
authors.lastname: Zhao
authors.affiliation: Department of Internal Medicine, The No.Three People's Hospital of Henan, Henan, China.
authors.forename: X F
authors.initials: XF
authors.lastname: Mao
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: dingmingwan@hotmail.com.
authors.forename: D M
authors.initials: DM
authors.lastname: Wan
authors.affiliation: Department of Hematology and Oncology, Children's Hospital of Zhengzhou, Zhengzhou, China. Electronic address: xyxf03@126.com.
authors.forename: W
authors.initials: W
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000008:administration & dosage*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006086:Graft vs Host Disease; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan